BrightGene Bio Book Value Per Share vs. Shares Owned By Institutions
| 688166 Stock | 29.55 0.68 2.36% |
For BrightGene Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BrightGene Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BrightGene Bio Medical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BrightGene Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BrightGene Bio Medical over time as well as its relative position and ranking within its peers.
BrightGene |
BrightGene Bio Medical Shares Owned By Institutions vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BrightGene Bio's current stock value. Our valuation model uses many indicators to compare BrightGene Bio value to that of its competitors to determine the firm's financial worth. BrightGene Bio Medical is number one stock in book value per share category among its peers. It also is number one stock in shares owned by institutions category among its peers producing about 3.25 of Shares Owned By Institutions per Book Value Per Share. Comparative valuation analysis is a catch-all model that can be used if you cannot value BrightGene Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BrightGene Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BrightGene Shares Owned By Institutions vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
BrightGene Bio |
| = | 5.57 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
BrightGene Bio |
| = | 18.13 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
BrightGene Shares Owned By Institutions Comparison
BrightGene Bio is currently under evaluation in shares owned by institutions category among its peers.
BrightGene Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BrightGene Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BrightGene Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BrightGene Bio's important profitability drivers and their relationship over time.
Use BrightGene Bio in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BrightGene Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BrightGene Bio will appreciate offsetting losses from the drop in the long position's value.BrightGene Bio Pair Trading
BrightGene Bio Medical Pair Trading Analysis
The ability to find closely correlated positions to BrightGene Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BrightGene Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BrightGene Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BrightGene Bio Medical to buy it.
The correlation of BrightGene Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BrightGene Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BrightGene Bio Medical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BrightGene Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BrightGene Bio position
In addition to having BrightGene Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Recreation theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BrightGene Stock
To fully project BrightGene Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BrightGene Bio Medical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BrightGene Bio's income statement, its balance sheet, and the statement of cash flows.